This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Photodynamic Therapy for Benign Dermal Neurofibromas

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Harry T Whelan, MD, Medical College of Wisconsin
Sponsor:
Information provided by (Responsible Party):
Harry T Whelan, MD, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT02728388
First received: March 25, 2016
Last updated: August 10, 2017
Last verified: August 2017
  Purpose

The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1).

The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.


Condition Intervention Phase
NEUROFIBROMATOSIS 1 Procedure: PDT Treatment Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II

Resource links provided by NLM:


Further study details as provided by Harry T Whelan, MD, Medical College of Wisconsin:

Primary Outcome Measures:
  • Time to disease progression [ Time Frame: 3 years ]
    The time it takes for 50% growth in tumor size over baseline measurements.


Secondary Outcome Measures:
  • Tumor growth rate [ Time Frame: 3 years ]
    Measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.


Estimated Enrollment: 30
Study Start Date: August 2016
Estimated Study Completion Date: August 2023
Estimated Primary Completion Date: August 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PDT Treatment

Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.

After 24 hours, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes).

Procedure: PDT Treatment

Drug: Levulan Kerastick

Drug: Topical placebo

Device: Omnilux Revive

Procedure: Photodynamic therapy

Other: Tumor growth rate measurements


Detailed Description:

Neurofibromas contain a large quantity of fibrous matter, and it is not anticipated that significant reductions in tumor size can be achieved in large, long established, tumors. Cutaneous neurofibromas, which do not usually become apparent until puberty, continue to increase in size and number throughout adulthood. The psychosocial burden of these disfiguring tumors is significant, and the targeted age group (14-30) is at a life period associated with an acceleration in tumor growth. It is for these reasons that the investigators hope to affect the growth rate of less established tumors, in order to prevent or lessen this burden as the patient progresses further into adulthood.

Therefore, the investigators wish to determine the time to disease progression (defined as 50% growth in size over baseline) for benign neurofibromas treated with PDT in patients with neurofibromatosis type 1 (NF1) in subjects aged 14-30.

The treatment will consist of choosing several neurofibromas of similar size, and applying a topical drug called Levulan, or just the topical application alone (a placebo). After 1 day, the neurofibromas will be illuminated with red light (both Levulan and placebo). The Levulan is what is known as a photosensitizer, and will be activated by the red light to potentially kill some of the tumor cells. Every 4 months after, for three years, the tumors will be measured to see if they are growing more slowly than the ones with the placebo application alone.

  Eligibility

Ages Eligible for Study:   14 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is 14 years or older.
  2. Diagnosed NF1, determined by American Academy of Neurology Guidelines (see Diagnosis section).
  3. Tumor Location: cutaneous, trunk, or limbs only.
  4. Tumor Type: superficial dermal neurofibromas ≤4mm deep.
  5. Patient has provided written informed consent.
  6. Patient is willing to and can comply with study follow-up requirements.
  7. Absence of any other malignancy.

Exclusion Criteria:

  1. Life expectancy less than 3 years.
  2. Pregnancy.
  3. Cutaneous photosensitivity to the wavelengths used to active PDT.
  4. A diagnosis of porphyria.
  5. Allergy to aminolevulinic acid or any of the topical solution vehicle components.
  6. Previous chemotherapy within 6 weeks of proposed PDT.
  7. Other concurrent tumor therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02728388

Contacts
Contact: Harry T Whelan, MD 414-266-7540 hwhelan@mcw.edu

Locations
United States, Wisconsin
The Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Harry T Whelan, MD    414-266-7540    hwhelan@mcw.edu   
Sponsors and Collaborators
Harry T Whelan, MD
Investigators
Principal Investigator: Harry T Whelan, MD Medical College of Wisconsin
  More Information

Responsible Party: Harry T Whelan, MD, Bleser Professor of Neurology, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT02728388     History of Changes
Other Study ID Numbers: PRO00026795
Study First Received: March 25, 2016
Last Updated: August 10, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Harry T Whelan, MD, Medical College of Wisconsin:
NF1
Neurofibroma
Neurofibromatosis Type 1

Additional relevant MeSH terms:
Neurofibromatoses
Neurofibroma
Nerve Sheath Neoplasms
Neurofibromatosis 1
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on September 19, 2017